Fixing essential medicine shortages: obstacles and opportunities

Global health experts and governing bodies agree that everyone has a right to access the medicines they need. The COVID-19 pandemic and resulting drug shortages have underscored the critical need to protect this right…
Investing in the next wave of biomanufacturing technologies for pharma

The global pandemic has brought pharmaceutical manufacturing to the forefront of America’s public consciousness. Acute drug shortages brought on by COVID-19 have underscored the need for domestic production and more resilient supply chains…
Meet the Team – Our Lab Operations Team

For the final installation in our “Meet the Team” series, we hear from Olivia, Khurram and Vicky, who lead our operations. This team is the key to ensuring Antheia’s labs are running successfully and efficiently…
Scaling synthetic biology as a manufacturing platform

For decades, synthetic biology has promised to make manufacturing more efficient, sustainable, and responsive to sudden changes in supply and demand. It has the potential to create new value across industries by transforming everything from food to pharmaceuticals…
Meet the Team – Our Engineer, Yuki Higa

For the next installation in the “Meet the Team” series, we hear from Yuki Higa, a Process Engineer at Antheia. Read on to learn about Yuki’s fast-paced work in a downstream processing group…
Meet the Team – Our RA, Cat Cleto

We’re excited for the next interview in our “Meet the Team” series! We hear from Cat Cleto, a Fermentation Research Associate, on her path from the world of retail to biotech and what she’s looking forward to over the next year…
Antheia at SynBioBeta 2020

Earlier this month, my cofounder Kristy Hawkins and I presented at SynBioBeta 2020, the flagship conference for the synthetic biology community. This year’s virtual event brought together academics, industry veterans…
Meet the Team – Our Scientist, Ken Takeoka

As a part of our new “Meet the Team” series, we hear from Ken Takeoka, Antheia’s very first employee and a Scientist III. Read on to learn about Ken’s path to Antheia and what he’s looking forward to over the next few years…
A Milestone for Drug Manufacturing and Synthetic Biology: Stanford Research Published in Nature

It’s a momentous day for my research team at Stanford University. Today, we’ve announced a new paper published in Nature that describes the first successful microbial biosynthesis of the tropane alkaloids hyoscyamine and scopolamine…
Three plant-based pharmaceuticals: taxol, scopolamine and buprenorphine

Over the last 150 years, the pharmaceutical industry has focused on decoupling the production of medicinal compounds from their sources in the natural world, which are susceptible to unpredictable swings in supply due to natural events like wildfires, drought or floods…